Also, the end of the maze ramps up, so “you kinda get a view over the top of the maze, so you get a little bit of appreciation of the design and what you’re actually walking through ...
Beyond MZE829, Maze's pipeline includes MZE782, an SLC6A19 inhibitor targeting chronic kidney disease and phenylketonuria, with Phase I data expected in the second half of 2025. Analysts view it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback